Syngene International Ltd

{"amount":1.25}

{"amount":1.25}

{"actualRevenue":9106000000,"estimateRevenue":9637000000,"revenueSurprise":-531000000,"revenueSurprisePercent":-5.51001348967521,"actualEPS":1.67,"estimateEPS":2.142,"surprise":-0.4720000000000004,"surprisePercent":-22.03548085901029}

{"actualRevenue":8745000000,"estimateRevenue":8677000000,"revenueSurprise":68000000,"revenueSurprisePercent":0.7836809957358535,"actualEPS":2.15,"estimateEPS":1.7697,"surprise":0.3802999999999999,"surprisePercent":21.48951799740068}

{"actualRevenue":9171000000,"estimateRevenue":9995000000,"revenueSurprise":-824000000,"revenueSurprisePercent":-8.244122061030515,"actualEPS":2.7,"estimateEPS":2.4378,"surprise":0.2622,"surprisePercent":10.75559931085405}

{"actualRevenue":10365000000,"estimateRevenue":9616000000,"revenueSurprise":749000000,"revenueSurprisePercent":7.78910149750416,"actualEPS":3.82,"estimateEPS":1.9482,"surprise":1.8718,"surprisePercent":96.07843137254902}

{"description":"On April 30, Syngene shares jumped up to 10% after Q4FY26 results: revenue +1.8% YoY to ₹1,037 cr, net profit -19.3% to ₹147.9 cr; Macquarie kept Outperform, PT ₹835.","url":"https://www.cnbctv18.com/market/syngene-international-share-price-jumps-10-percent-q4-results-check-macquarie-target-ws-l-19896357.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Syngene International shares fell 15% in two sessions, marking a nine-session losing streak with a total decline of 20%. The company's Q3 profit dropped nearly 90%, prompting Jefferies to downgrade the stock to 'underperform' and cut the price target to ₹480.","url":"https://www.cnbctv18.com/market/syngene-international-share-price-ninth-day-of-losses-q3-results-jefferies-downgrade-target-cut-19833689.htm","sentiment":"Negative","domain":"CNBCTV18"}

{"description":"Syngene International has extended its research partnership with Bristol Myers Squibb until 2035, enhancing collaboration in drug development. This partnership, which began in 1998, aims to improve patient outcomes and streamline drug candidate progression. Macquarie maintains an 'outperform' rating on Syngene with a target price of ₹835, indicating a potential upside of 28%.","url":"https://www.cnbctv18.com/market/syngene-extends-bristol-myers-squibb-research-partnership-till-2035-ws-l-19823484.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Syngene International shares rose 3.6% on January 7, 2026, after Macquarie maintained an 'outperform' rating with a target price of ₹835, suggesting a 27% upside. The firm anticipates improved fundamentals and growth in Syngene's CRO and CDO segments despite past declines.","url":"https://www.cnbctv18.com/market/syngene-share-price-macquarie-finds-risk-reward-attractive-buy-target-upside-triggers-19815901.htm","sentiment":"Positive","domain":"CNBCTV18"}